Skip to main content
. Author manuscript; available in PMC: 2023 May 5.
Published in final edited form as: Cell Stem Cell. 2022 May 5;29(5):760–775.e10. doi: 10.1016/j.stem.2022.04.007

Figure 2. Mouse HSPCs present self-antigens via MHC-II.

Figure 2.

See also Figure S1.

(A) Ex vivo antigen presentation assay. Representative histograms (left) and quantification (right), n=4.

(B and C) In vivo antigen presentation assay, n=6. (B) Heatmap summarizing the percentage of Eα presenting cells in C57BL/6xBALB/c mice and control C57BL/6 mice. (C) Quantification of selected populations in C57BL/6xBALB/c.

(D-F) Mass spectrometry analyses of peptides recovered from MHC-II of indicated populations. (D) MHC-II-eluted peptide size distribution. (E) Gene set enrichment analysis (GSEA) of presented peptides related to their gene expression in HSPCs. (F) MHC-II-derived peptides in HSPCs that are transcribed (endogenous) or not transcribed (exogenous) within HSPCs based on a threshold of 100 RPKM.

Individual values are shown in B and D, means and SEM are depicted otherwise. No significance = ns, P<0.05 *, P<0.01 **, P<0.001 ***, P<0.0001 ****. One- (A) or two-way ANOVA (C) were performed as discovery tests. Paired two-tailed t-test was performed in C. If not stated otherwise, unpaired two-tailed t-tests were performed as post-hoc tests.